EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rethinking MRI Protocols for Pituitary Microadenomas: Prioritizing Non-Contrast Imaging for Safe Follow-Up

Fariba Zarei, Farideh Nematollahi, Asadolah Jalil, Banafsheh Zeinali-Rafsanjani, Mahdi Saeedi-Moghadam

Tomography · 2025

DOI: 10.3390/tomography11090105 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Tomography, 2025. Verfasst von Fariba Zarei und 4 weiteren Autor:innen. Beteiligte Einrichtung: Medical Imaging Research Center, Shiraz University of Medical Sciences, Shiraz 71936-35899, Iran. Hauptthemen laut MEDLINE: Magnetic Resonance Imaging, Pituitary Neoplasms, Adenoma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objectives: Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) has been used as a gold standard in diagnosing and following pituitary microadenomas. However, the use of gadolinium-based contrast agents (GBCAs) involves a potential risk of long-term retention in tissues and adverse reactions. This study aimed to evaluate the sensitivity of non-contrast MRI (T1W and T2W sequences) in follow-up imaging of pituitary microadenomas, attempting a comparison with DCE-MRI, assessing tumor stability over time. Materials and methods: We retrospectively reviewed 300 pituitary MRI scans between 2020 and 2024. Included were patients with confirmed microadenomas (≤10 mm). Non-contrast (T1W/T2W) and DCE-MRI sequences were analyzed by an experienced radiologist blinded to any clinical information. Detection rates and changes in tumor size were evaluated.

Results

Detection rates for 79 microadenomas were 55.7% for T1W, 70.9% for T2W, and 88.6% for DCE-MRI. There was no significant tumor growth during the follow-up (mean size 4.80 ± 2.3 mm vs. 4.81 ± 2.4 mm, p > 0.5).

Conclusions

While still more sensitive for the primary diagnosis, the non-contrast MRI was able to visualize the majority of detected microadenomas, and significant growth was ruled out, thus supporting the case to omit gadolinium from follow-up imaging in stable cases. This may translate to lower costs and decreased patient risk from contrast-related hazards.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Magnetic Resonance ImagingPituitary NeoplasmsAdenomaHumansFemaleRetrospective StudiesMaleMiddle AgedContrast MediaAdultFollow-Up StudiesAgedGadoliniumSensitivity and SpecificityPituitary Gland

Stichwörter der Autor:innen

dynamic MRIgadoliniummicroadenomanon-contrast MRIpituitary adenoma

Substanzen

Contrast MediaGadolinium

Autor:innen und Institutionen

  • Medical Imaging Research Center, Shiraz University of Medical Sciences, Shiraz 71936-35899, Iran.
  • Department of Radiology, Shiraz University of Medical Sciences, Shiraz 71936-35899, Iran.

Zitieren

APA

Zarei, F., Nematollahi, F., Jalil, A., Zeinali-Rafsanjani, B., & Saeedi-Moghadam, M. (2025). Rethinking MRI Protocols for Pituitary Microadenomas: Prioritizing Non-Contrast Imaging for Safe Follow-Up. Tomography. https://doi.org/10.3390/tomography11090105

Vancouver

Zarei F, Nematollahi F, Jalil A, Zeinali-Rafsanjani B, Saeedi-Moghadam M. Rethinking MRI Protocols for Pituitary Microadenomas: Prioritizing Non-Contrast Imaging for Safe Follow-Up. Tomography. 2025. doi:10.3390/tomography11090105

BibTeX
@article{Zarei2025,
  author = {Zarei, Fariba and Nematollahi, Farideh and Jalil, Asadolah and Zeinali-Rafsanjani, Banafsheh and Saeedi-Moghadam, Mahdi},
  title = {Rethinking MRI Protocols for Pituitary Microadenomas: Prioritizing Non-Contrast Imaging for Safe Follow-Up},
  journal = {Tomography},
  year = {2025},
  doi = {10.3390/tomography11090105}
}
Kostenlos starten →